Table 1.
Clinical characteristics of CHD patients.
| Items | CHD patients (N = 410) |
|---|---|
| Demographics | |
| Age (years), mean ± SD | 62.9 ± 9.9 |
| Gender, No. (%) | |
| Female | 122 (29.8) |
| Male | 288 (70.2) |
| BMI (kg/m2), mean ± SD | 25.5 ± 3.1 |
| History of smoke, No. (%) | |
| Never | 207 (50.5) |
| Former | 120 (29.3) |
| Current | 83 (20.2) |
| Medical history | |
| History of hypertension, No. (%) | |
| No | 122 (29.8) |
| Yes | 288 (70.2) |
| History of hyperlipidemia, No. (%) | |
| No | 233 (56.8) |
| Yes | 177 (43.2) |
| History of DM, No. (%) | |
| No | 306 (74.6) |
| Yes | 104 (25.4) |
| History of CKD, No. (%) | |
| No | 339 (82.7) |
| Yes | 71 (17.3) |
| Biochemical indexes | |
| FBG (mmol/L), median (IQR) | 6.0 (5.2–7.0) |
| Scr (μmol/L), median (IQR) | 84.7 (75.3–93.3) |
| SUA (μmol/L), median (IQR) | 353.0 (305.0–410.3) |
| TG (mmol/L), median (IQR) | 1.8 (1.1–2.5) |
| TC (mmol/L), median (IQR) | 4.9 (4.2–5.7) |
| LDL-C (mmol/L), median (IQR) | 3.5 (2.9–4.3) |
| HDL-C (mmol/L), median (IQR) | 0.9 (0.8–1.1) |
| CRP (mg/L), median (IQR) | 5.6 (3.9–8.1) |
| Disease characteristics | |
| Gensini score, median (IQR) | 32.3 (17.0–50.1) |
| Stenosis degree | |
| Mild (Gensini score <32), No. (%) | 199 (48.5) |
| Moderate (Gensini score 32–56), No. (%) | 124 (30.2) |
| Severe (Gensini score >56), No. (%) | 87 (21.3) |
| Inflammatory cytokines | |
| TNF-α (pg/ml), median (IQR) | |
| IL-1β (pg/ml), median (IQR) | 1.0 (0.6–1.5) |
| IL-6 (pg/ml), median (IQR) | 16.9 (12.6–26.7) |
| IL-17A (pg/ml), median (IQR) | 58.6 (43.7–90.9) |
| Current treatment information | |
| Antiplatelet therapy | 410 (100.0) |
| β-Blocker | 289 (70.5) |
| Calcium channel blockers | 116 (28.3) |
| Statin or other lipid-lowering therapy | 177 (43.2) |
| ACEI or ARB | 157 (38.3) |
SD, standard deviation; Scr, serum creatinine; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol.